Claudio Costamagna

Chairman

Claudio Costamagna is the Chairman of our Board and was appointed to our board in January 2010. He is the Founder and Chairman of the financial advisory boutique CC&Co. and Chairman of CDP (Cassa depositi e prestiti). He also sits on the Board and is the Chair of the Compensation Committee of FTI Consulting inc. a company listed on the NYSE. He previously held senior positions at Citigroup, Montedison and, most recently, Goldman Sachs, where he served until 2006 as Chairman of the Investment Banking division for Europe, the Middle East and Africa. He has served as Independent Board Member of several public companies including, among others, Luxottica Group, Bulgari S.p.A. and Virgin Group Holding. Mr. Costamagna holds a degree in Business Administration from Università Bocconi in Milan.

Stefano Buono

CEO

Stefano Buono is the Chief Executive Officer, a member of our board of directors, and a founder of AAA. Prior to founding AAA in 2002, Mr. Buono worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4. During his six years with CRS4, Mr. Buono headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. For approximately ten years, he worked with Physics Nobel Laureate Carlo Rubbia at CERN, the world’s largest research laboratory for particle physics. He actively participated in the development of CERN’s Adiabatic Resonance Crossing method. He is the author of numerous scientific papers. Mr. Buono received his masters degree in physics from the Universita degli Studi di Torino in Turin, Italy in 1991.

François Nader

Non-Executive Director

François Nader became a member of our board of directors in May 2016. François Nader, M.D., has over 30 years of experience in the global biopharmaceutical industry in senior operational and scientific roles. From 2008 to 2015, Dr. Nader served as the President and Chief Executive Officer of NPS Pharmaceuticals, Inc. and previously served as Chief Operating Officer in 2007, and Chief Medical and Commercial officer in 2006. During his tenure as CEO, Dr. Nader transformed NPS into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases until Shire acquired the company for $5.2B in February 2015. Dr. Nader was recognized as the EY US National Life Science Entrepreneur of the Year® in 2013. Before joining NPS, Dr. Nader was a venture partner at Care Capital. Prior to that, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions in the U.S. and Canada, including Senior Vice President, U.S. integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon in 1981 and his Physician Executive MBA from the University of Tennessee in 2000.

Christine Mikail

Non-Executive Director

Christine Mikail became a member of our board of directors in May 2017. She has over fifteen years of experience managing and advising a number of public and private biotech and pharmaceutical companies focusing in the legal and business development functions. Ms. Mikail is the founder of DCA Advisory where she is currently advising several start-up and private biotech companies. She is also an Adjunct Professor at the Rutgers Business School in New Jersey. From March 2015, to March 2017, she was Chief Administrative Officer, Head of External Business Development and Alliance Management, and General Counsel at Axovant Sciences, Inc., where she helped raise $362 million in one the largest biotech Initial Public Offerings. Prior to this, Ms. Mikail served as Senior Vice President of Legal Affairs, General Counsel and Secretary at NPS Pharmaceuticals, Inc., where she was an integral part of the deal team that sold NPS Pharma to Shire Pharmaceuticals for $5.2 billion. Ms. Mikail’s other positions included senior leadership roles at Dendreon Corporation, Savient Pharmaceuticals, ImClone Systems Corporation and later Eli Lilly, following the acquisition of ImClone. Prior to joining the pharmaceutical industry, Ms. Mikail practiced law at Reed Smith, LLP, Lowenstein Sandler PC, and Wilmer Hale. Ms. Mikail holds a Juris Doctorate from Fordham Law School and a Bachelor of Arts degree from Rutgers University.

Steven Gannon

Non-Executive Director

Steven Gannon became a member of our board of directors in June 2014. He was a Senior Vice President and the Chief Financial Officer and Treasurer at Aptalis Pharma Inc. until February 2014, after which it was sold to Forest Laboratories. Prior to joining Aptalis Pharma Inc. in 2006, Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies, Inc. from 1999 to 2006, as the Director of Finance and Administration of the Research Division of Astrazeneca Canada Inc. from 1996 to 1999, and as the Chief Financial Officer of Mallinckrodt Medical Inc.’s Canadian operations from 1989 to 1995. He received a bachelor of commerce in accounting and business systems from Concordia University in Montreal, Canada in 1983, and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a chartered accountant since 1985.

Kapil Dhingra

Non-Executive Director

Kapil Dhingra became a member of our board of directors in March 2014. Dr. Dhingra founded and is the head of KAPital Consulting, a healthcare consulting firm. Dr. Dhingra also serves on several emerging life science company boards, including Exosome Diagnostics Inc., and Epitherapeutics ApS. He also recently joined the board of Nasdaq listed Five Prime Therapeutics, Inc. He previously served on the Boards of several successful companies, including Biovex, Micromet, Algeta, and, YM Biosciences, that were acquired by major pharmaceutical companies. Prior to joining AAA, Dr. Dhingra worked for over 25 years in oncology clinical research and drug development. His experience includes nine years at Hoffman-La Roche, where he served in various positions, including Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development. Prior to that, he worked as a Senior Clinical Research Physician at Eli Lilly and Company. Dr. Dhingra specialized in internal medicine and medical oncology. He holds an MD (MBBS) degree from the All India Institute of Medical Sciences in New Delhi, India, with subsequent residency in internal medicine at Lincoln Medical and Mental Health Center in New York City, New York and New York Medical College in Valhalla, New York, and was a Fellow in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia.

Christian Merle

Non-Executive Director

Christian Merle became a member of our board of directors in June 2014. Mr. Merle is the Managing Partner of Merle & Partners. Prior to founding Merle & Partners in 2014, Mr. Merle was the Chief Executive Officer of Banque Espirito Santo from 2007 to 2013, the Managing Partner of Gimar & Cie from 2003 to 2007 and the Chief Executive Officer of Banca Intesa from 1998 to 2003. Prior to joining Banca Intesa, he served in various roles at Credit Agricole, including as the Executive Vice President of Credit Agricole Indosuez. He also served in various roles in the French Treasury, including the Chief Representative in the United States from 1987 to 1990. He received his undergraduate degree from the Institut d’Etudes Politique de Paris in 1974 and a master’s degree in economics from the Université de Paris I-Panthéon Sorbonne in 1975, both in Paris, France.

Leopoldo Zambeletti

Non-Executive Director

Leopoldo Zambeletti became a member of our board of directors in June 2014. Mr. Zambeletti is an independent financial advisor in the Life Science sector. In this capacity he has advised various companies on corporate finance matters including advising Nogra Pharma in the largest ever out licensing to Celgene for a compound in development. Prior to becoming an advisor, Mr. Zambeletti was a managing director and Head of European, India and MENA Healthcare Investment Banking at Credit Suisse and a managing director and the Head of the Ultra High Net Worth group at Credit Suisse’s investment bank from 2007 to 2012. From 1994 to 2007, he held various positions at J.P. Morgan, including as Head of Healthcare Investment Banking. He received a bachelor’s degree in business administration from the Università Commerciale Luigi Bocconi in Milan, Italy in 1992. Mr. Zambeletti serves as a member of the board of directors of Nogra Pharma, Summit Therapeutics and Qardio. He is also a trustee of Saint Barts and the London Charity.

This website uses cookies to improve the user experience of the site. By using the site, you agree to accept our use of cookies. If you require further information or do not wish to accept our use of cookies, visit our Website Privacy Policy page×